NeuroVoices

The chief medical officer of Scholar Rock provided background on the company’s investigational SMA treatment and its clinical benefit when applied with nusinersen (Spinraza; Biogen).

The pediatric headache specialist at NYU Langone discussed how pediatric migraine is currently treated, the signs and symptoms associated, and whether awareness levels are where they need to be.

The duo from Cleveland Clinic addressed several of their research projects presented at AHS 2021 that covered a range of COVID-19 related topics, including the unknowns about associated headaches.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.

The founder and chief scientific officer of Neurolutions discussed other populations that may benefit from the IpsiHand Upper Extremity Rehabilitation System by building on its current capabilities.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed the significance of World MS Day and how clinical care of MS has evolved.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients.

The assistant professor of neurology at the Weill Cornell Brain and Spine Center discussed his presentation at AAN 2021 evaluating racial disparities in smoking cessation among stroke survivors.

The professor of neurology at Mayo Clinic discussed the need for understanding more about how social determinants of health can impact epilepsy treatment delays.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed solutions to improve disparities in stroke care and the need for future research on social determinants of health.

The consultant in the department of neurology at Mayo Clinic detailed a number of topics surrounding Parkinson Disease Awareness Month, including the progress made in the last 2 decades.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.

The duo from Montefiore Medical Center discussed a variety of topics surrounding an effort to improve seizure diagnosis and classification in newborns.

The postdoctoral researcher at Columbia University detailed a number of topics regarding the impact concealing multiple sclerosis diagnosis can have on a patient.

The director of the Institute for Health, Health Care Policy and Aging Research at Rutgers University discussed a recently published report on meeting the challenge of caring for persons with dementia and their care partners and caregivers.

The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.

The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

The duo from Vanderbilt University shared background on their recently published study that found novel associations between functional seizures, cerebrovascular disease, and other psychiatric disorders.

Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Raymond Sanchez, MD, chief medical officer of Cerevel Therapeutics, discussed tavapadon, a drug intended to treat Parkinson disease that is currently being tested in a slew of clinical trials.

Jennifer Robblee, MD, neurologist, Barrow Neurological Institute, shares her takeaways about how migraine care shifted this year and how it may continue to shift going forward.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the findings of a phase 2 trial using ezogabine, a drug once FDA-approved to treat epilepsy, in patients with ALS.